Podcasts by Category
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda
- 233 - LCC and Smoking Cessation
May 31st is World No Tobacco Day and to observe this, Lung Cancer Considered host Dr. Narjust Florez leads a discussion on smoking cessation and how to honor the need for smoking cessation counseling without contributing to stigma. Smoking tobacco products (primarily cigarettes) is an important risk factor for the development of lung cancer and secondhand smoke is also a significant cause of lung cancer. Worldwide, smoking accounts for approximately two-thirds of lung cancer cases
Fri, 31 May 2024 - 34min - 232 - Lung Cancer Considered--Smoking Cessation
May 31st is World Tobacco Day and the IASLC podcast "Lung Cancer Considered" features a leading expert on smoking cessation, Dr. Kathryn Taylor. Dr. Taylor is behavioral scientist and a Professor in the Department of Oncology at the Georgetown Lombardi Comprehensive Cancer Center in Washington DC Smoking tobacco products (primarily cigarettes) is an important risk factor for the development of lung cancer. Secondhand smoke is also a significant cause of lung cancer. Worldwide, smoking accounts for approximately 2/3 of lung cancer cases with the remaining occurring due to other causes.
Fri, 31 May 2024 - 34min - 231 - LCC in French CanadianFri, 24 May 2024 - 39min
- 230 - Virtual Tumor Board: PD-L1 Low NSCLC
In this virtual tumor board episode, host Dr. Stephen Liu leads a discussion about the management of metastatic, PD-L1 low NSCLC. Dr. Apar Ganti is a Professor of Medicine at the University of Nebraska Medical Center and the Associate Director for Clinical Research at the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska. Dr. Sze-Wai Chan from the Sandton Oncology Centre in Johannesburg, South Africa, where she is the Director and Head of Clinical Trial Research.
Tue, 21 May 2024 - 33min - 229 - When two worlds collide: Adenosquamous histology
In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion about adenosquamous cell carcinoma of the lung, from diagnosis, treatment, and outcomes in this group of patients.
Tue, 07 May 2024 - 39min - 228 - KRAS in NSCLC: Beyond G12C
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, other than G12C. This form of lung cancer varies by geography and incidence. KRAS mutations were once thought undruggable, but KRAS inhibitors are now available. However, not all forms of KRAS mutant lung cancers are the same and clinicians need to be aware of the difference between KRAS mutations.
Tue, 30 Apr 2024 - 46min - 227 - FDA Approval: Adjuvant Alectinib for Resected NSCLC
In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.
Thu, 18 Apr 2024 - 38min - 226 - IASLC DEI Initiative Global Member Survey
As part of the IASLC’s 2024 DEI Initiative, the association is gathering member insights through an online survey and a series of virtual focus groups designed to help the organization better understand the challenges and areas for opportunity facing the global thoracic oncology profession. To take the survey, visit: https://www.iaslc.org/support-mission/iaslc-dei-initiative-global-member-surve
Tue, 16 Apr 2024 - 27min - 225 - FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2 was first presented at the 2023 WCLC in Singapore by Dr. Jänne.
Tue, 02 Apr 2024 - 47min - 224 - ELCC 2024 Highlights
This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Prague. Host Dr. Stephen Liu discusses the important research presented at the meeting with Dr. Jeff Bradley, Dr. Hazel O’Sullivan, and Dr. Antonio Calles.
Thu, 28 Mar 2024 - 58min - 223 - Emerging Agents In Small Cell Lung Cancer
Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive-stage disease. Unlike non-small cell lung cancer, treatments are more limited. Fortunately, the field continues to advance and there are several novel agents showing promise. In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses some of these promising therapies with Dr. Anne Chiang and Dr. Luis Paz-Ares.
Tue, 19 Mar 2024 - 41min - 222 - Radiopharmaceuticals and Lung Cancer
This episode of Lung Cancer Considered focuses on radiopharmaceuticals-- a unique class of drugs that may have the most immediate impact in neuroendocrine tumors. Host Dr. Stephen Liu leads a discussion with three respected international clinicians about how these therapies play a role in both diagnostics and therapeutics and how they may soon be expanding.
Tue, 05 Mar 2024 - 54min - 221 - FDA Approval: 1L Amivantamab plus Chemotherapy for EGFR Exon 20 NSCLC
Amivantamab Approved by FDA today, March 1! In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCLC with an EGFR exon 20 insertion, based on the phase III PAPILLON trial. These data were first shared at ESMO 2023 in Madrid with a simultaneous publication in the New England Journal of Medicine.
Fri, 01 Mar 2024 - 28min - 220 - Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC
Today’s episode of Lung Cancer Considered is part of our special series on seminal trials in thoracic oncology, focusing on the phase I study of the PD-1 inhibitor nivolumab. Hosts Dr. Narjust Florez and Dr. Stephen Liu discuss that study with guest Dr. Julie Brahmer from Johns Hopkins University. This podcast features surprise guest interviews with several doctors who were mentored by Dr. Brahmer.
Thu, 29 Feb 2024 - 32min - 219 - From the Basics to Next Line Therapy: ALK + NSCLC
ALK fusions represent 3-5% of newly diagnosed non-small cell lung cancers but several therapeutic options do exist. Lung Cancer Considered host Dr. Narjust Florez and guests Dr. Christine Lovly from Vanderbilt University and Yvonne Diaz from Oncogene Cancer Research discuss how an ALK positive diagnosis is made and what therapies are currently available to treat it.
Tue, 27 Feb 2024 - 46min - 218 - Best Practice for RET NSCLC
Lung Cancer Considered Host Dr. Stephen Liu moderates a discussion in this podcast on RET as a therapeutic target. RET fusions are a known actionable alteration and this field has blossomed very quickly. He is joined on the podcast by Dr. Oliver Gautschi from the University of Bern and Cancer Center Lucerne in Switzerland and Dr. Mihaela Aldea from Gustave Roussy in France.
Tue, 20 Feb 2024 - 34min - 217 - Biomarkers in Lung Cancer: Barriers to Implementation
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found that one-third of oncologists were unaware of evidence-based guidelines for these tests. To discuss the importance of this survey and its underlying issues, host Dr. Stephen Liu discusses some of the barriers to biomarker testing with Dr. Debora Bruno, Dr. Rami Manochakian, and Dr. Matthew Smeltzer. To take the survey, visit: https://bit.ly/BiomarkerS24
Fri, 16 Feb 2024 - 45min - 216 - LCC in Cantonese Chinese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Sally Lau leads a discussion in Cantonese about barriers to biomarker testing with Dr. Herbert Loong and Dr. Molly Li. To take the survey, visit: https://bit.ly/BiomarkerS24
Fri, 16 Feb 2024 - 39min - 215 - LCC in Mandarin Chinese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin about biomarker testing with Dr. Bo Zhu and Dr. Yuan Li. To take the survey, visit: https://bit.ly/BiomarkerS24
Fri, 16 Feb 2024 - 28min - 214 - LCC in French Canadian: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Norman Blais moderates a discussion about biomarker testing in French Canadian with Dr. Arielle Elkrief and Dr. Nicolas Marcoux. To take the survey, visit: https://bit.ly/BiomarkerS24
Fri, 16 Feb 2024 - 45min - 213 - LCC in Portuguese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Clarissa Mathias leads a discussion in Portuguese about biomarker testing with Dr. Vladmir Lima and Dr. Aknar Calabrich. To take the survey, visit: https://bit.ly/BiomarkerS24
Fri, 16 Feb 2024 - 36min - 212 - LCC in French: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for biomarker tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Alfredo Addeo discussed barriers to biomarker testing in French with Dr. Solange Peters and Dr. Maurice Perol. To take the survey, visit: https://bit.ly/BiomarkerS24
Fri, 16 Feb 2024 - 39min - 211 - LCC in Japanese: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To promote the survey to a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Misako Nagasaka leads a discussion in Japanese about biomarker testing with Dr.Terufumi Kato and Dr. Masahiro Tsuboi. To take the survey, visit: https://bit.ly/BiomarkerS24
Wed, 14 Feb 2024 - 33min - 210 - LCC in Spanish: Barriers to Biomarker Testing
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. To discuss the importance of this survey and its underlying issues, host Dr. Narjust Florez discusses some of the barriers to biomarker testing in Spanish with Dr. Ivy Riano and Dr. Teresa Gorría. To take the survey, visit: https://bit.ly/BiomarkerS24
Sat, 10 Feb 2024 - 38min - 209 - The IASLC’s 50th Anniversary and New Strategic Plan
2024 is the 50th anniversary of the International Association for the Study of Lung Cancer and as we enter this monumental year for IASLC, we do so under a new strategic plan. To discuss what the future of IASLC looks like, hosts Dr. Stephen Liu and Dr. Narjust Florez interview four IASLC leaders to provide a glimpse into where the association is headed.
Tue, 06 Feb 2024 - 37min - 208 - Lung Cancer in MENA: Clinical and Research Initiatives
Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as well as how new targeted therapies and immunotherapies assist oncologists as they treat patients with lung cancer.
Fri, 22 Dec 2023 - 27min - 207 - LCC in Cantonese: Biomarker Testing and EGFR Mutant NSCLC
Host Dr. Sally Lau, Thoracic Medical Oncologist and Assistant Professor at the New York University Perlmutter Cancer Center, leads a discussion, in Cantonese, about biomarker testing in lung cancer and the management of EGFR mutant NSCLC.
Fri, 02 Feb 2024 - 44min - 206 - Meet the New IASLC Chief Scientific Officer Dr. Jennifer King
Host Dr. Narjust Florez interviews new IASLC Chief Scientific Officer Dr. Jennifer King. In this podcast episode, Dr. King shares her perspective on how she intends to direct, guide, and support the scientific strategy of the IASLC.
Tue, 30 Jan 2024 - 39min - 205 - Lung Cancer in MENA: Clinical and Research Initiatives
Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as well as how new targeted therapies and immunotherapies assist oncologists as they treat patients with lung cancer.
Fri, 26 Jan 2024 - 28min - 204 - IASLC - Oligometastatic Lung Cancer Part 2
In Part Two of this Lung Cancer Considered podcast on Oligometastic NSCLC, host Dr. Narjust Florez and guest Dr. Daniel Gomez discuss treatment alternatives with local therapy, focusing on radiation.
Tue, 23 Jan 2024 - 37min - 203 - Lung Cancer Considered: A Three-Year Review
Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu host this retrospective look at the podcast, examining how the podcast started, how the team plans podcasts and what is in store for its future.
Fri, 19 Jan 2024 - 36min - 202 - IASLC Oligometastatic NSCLC
In Part 1 of a two-part podcast on Oligometastatic lung cancer and the treatment alternatives with local therapy, host Dr. Narjust Florez interviews Dr. Fatima Wilder about how local therapies, such as surgery, radiation and cryoablation impact treatment of this complex form of lung cancer.
Tue, 16 Jan 2024 - 29min - 201 - Maximizing Supportive Care in Lung Cancer
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guests discuss the importance of palliative care and psychological support for patients with lung cancer. Due to recent advances in lung cancer, we have reached a historic number of lung cancer survivors. Now more than ever, we need to ensure that patients receive appropriate support as they learn to live with lung cancer, lung cancer stigma, associated treatment side effects, and the idea of early mortality.
Tue, 26 Dec 2023 - 43min - 200 - IASLC Chronic Toxicity From Targeted TherapyTue, 19 Dec 2023 - 55min
- 199 - LCC in Korean: Managing EGFR+ NSCLC
Lung cancer experts in Korea discuss the unique challenges they face when treating patients with lung cancer with EGFR and non-small cell lung cancer.
Fri, 15 Dec 2023 - 50min - 198 - New Options for Initial Treatment of EGFR Mutant NSCLC
In this episode, host Dr. Stephen Liu leads a discussion on the current first-line treatment options for EGFR-mutant non-small cell lung cancer, including how new data from FLAURA2 and MARIPOSA may influence treatment approaches.
Tue, 12 Dec 2023 - 45min - 197 - Research from NACLC: Nutrition as Medicine and Lung Cancer Screening
IASLC Lung Cancer Considered host Dr. Narjust Florez interviews two researchers presenting at the North America Conference on Lung Cancer: Dr. Carolyn Presley is an Associate Professor in the Division of Medical Oncology/Department of Internal Medicine at The Ohio State University, Comprehensive Cancer Center and The James Cancer Hospital/Solove Research Institute. Alexandra Potter is co-founder and President of the American Lung Cancer Screening Initiative.
Fri, 08 Dec 2023 - 43min - 196 - FDA Approval: Repotrectinib, a ROS1 and NTRK inhibitor
Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.
Thu, 30 Nov 2023 - 37min - 195 - FDA Approval: Perioperative Pembrolizumab and KEYNOTE 671
Host Dr. Narjust Florez leads a discussion about the data from the KEYNOTE 671 trial, presented at ASCO 2023 and ESMO 2023, that led to the first approval of the combination of pembrolizumab plus chemotherapy in the neoadjuvant and adjuvant setting.
Tue, 28 Nov 2023 - 45min - 194 - It's time to talk about sexual health and lung cancer!
Sexual health of patients with lung cancer is poorly understood, highly prevalent, and not frequently discussed. However, sexual concerns are common in people with lung cancer, with many receiving very little information compared to patients diagnosed with cancer that affects a sexual or reproductive organ. In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion with two national experts on how patients with lung cancer can maintain their sexual health during and after lung cancer diagnosis and treatments.
Tue, 28 Nov 2023 - 39min - 193 - Virtual Tumor Board: Neoadjuvant for Stage III NSCLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the role of neoadjuvant therapy for stage III NSCLC using a virtual tumor board format. This area has become increasingly complex of late, as we have seen several large studies report encouraging results with peri-operative immunotherapy and targeted therapy.
Tue, 21 Nov 2023 - 47min - 192 - LCC in Dutch: Lung Cancer Care in The Netherlands
This episode of Lung Cancer Considered covers the current treatment and research landscape in The Netherlands. The episode is recorded in Dutch and is hosted by Dr. Lizza Hendriks from the Maastricht University Medical Center. Guests are Anne Marie Dingemans from Erasmus MC, Rotterdam, The Netherlands and Anthonie Vd Wekken from the University Medical Centre Groningen.
Fri, 17 Nov 2023 - 53min - 191 - AEGEAN and Beyond: Perioperative Immunotherapy for NSCLC
Lung Cancer Considered host Dr. Narjust Florez leads an informed discussion on the AEGEAN Trial, which explored neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resected NSCLC.
Tue, 14 Nov 2023 - 40min - 190 - Updated IASLC - Hindi
Title: Lung Cancer Care in India: Approaching a Lung Cancer Diagnosis (Hindi language podcast) The podcast is recorded in Hindi and covers a range of crucial lung cancer topics, including the emergence of adenocarcinoma as the dominant histological type, delays in diagnosis related to misdiagnosis as tuberculosis, and the importance of accurate staging and biomarker testing.
Fri, 10 Nov 2023 - 50min - 189 - FDA Approval: Encorafenib + Binimetinib in BRAF V600E NSCLC
In this podcast, host Dr. Stephen Liu moderates a discussion a recent FDA approval and a specific molecular subtype of NSCLC. On October 11, 2023, the US FDA granted approval to encorafenib and binimetinib for advanced NSCLC harboring a BRAF V600E mutation based on the phase II PHAROS trial.
Mon, 06 Nov 2023 - 42min - 188 - ESMO 2023 Highlights: Early Stage NSCLC, SCLC, Thymic Carcinoma
Part 2 of our podcast coverage on ESMO 2023 includes an in-depth interview with Dr. Jarushka Naidoo on early-stage NSCLC, including updates from CheckMate816, Keynote 671 overall survival results, and Checkmate77T, first perceptions about the data, remaining unanswered questions and how to incorporate to our clinical practice. Further, we discussed exciting data in the 2nd line setting for Small-Cell Lung Cancer and a new potential therapeutic option for thymic carcinoma. Tune in for this thought-provoking, data-driven, and practical episode of Lung Cancer Considered.
Wed, 01 Nov 2023 - 45min - 187 - ESMO 2023 Highlights: Metastatic NSCLC
In the first part of two podcasts covering recent data presented at the European Society of Medical Oncology Congress 2023, host Dr. Stephen Liu summarizes the most compelling research on metastatic non small cell lung cancer from the meeting with Dr. Zosia Piotrowska and Dr. Noemi Reguart, discussing several impactful studies including MARIPOSA, MARIPOSA-2, LIBRETTO-431, TROPION-Lung01 and more as well as reviewing the importance of CNS efficacy and the evolving role of antibody drug conjugates (ADCs).
Mon, 30 Oct 2023 - 45min - 186 - Lung Cancer Care and Research in Japanese
Today’s episode of Lung Cancer Considered is recorded entirely in Japanese and focuses on EGFR mutated lung cancer.
Fri, 27 Oct 2023 - 54min - 185 - Lung Cancer Considered--Hungarian Episode
In this special episode of Lung Cancer Considered recorded in Hungarian, lung cancer experts in Hungary and the United States discuss challenges and emerging strategies to treat lung cancer in Hungary.
Tue, 24 Oct 2023 - 1h 02min - 184 - IASLC - Mesothelioma
Mesothelioma is a particularly challenging cancer to treat and there had been relatively few updates in its management until the recent integration of immunotherapy into treatment guidelines. To discuss current strategies to treat Mesothelioma, Dr. Stephen Liu leads an informed discussion with two international Mesothelioma experts.
Tue, 17 Oct 2023 - 43min - 183 - NACLC 2023 Preview
In this episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu preview the 2023 North America Conference on Lung Cancer, scheduled for December in Chicago, December 1 - 3. The deadline for abstract submission is October 26th. Visit https://www.iaslc.org/2023-north-america-conference-lung-cancer to learn more.
Tue, 03 Oct 2023 - 18min - 182 - WCLC 2023 - Meeting Wrap Up
Lung Cancer Considered Hosts Dr. Narjust Florez and Dr. Stephen Liu wrap up WCLC 2023 in Singapore, discussing the meeting's most impactful research, including MARS2, FLAURA2, TRIDENT, HERTHENA, and TROPION.
Tue, 19 Sep 2023 - 49min - 181 - WCLC 2023 - Tuesday Highlights
Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu recap three important sessions from Tuesday, September 12th at the IASLC WCLC 2023: Advocates Unite to Increase Lung Cancer Research Funding An update on the AEGEAN Trial--Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable Long-term Outcomes by Radiation Technique for Locally Advanced Non-Small Lung Cancer: A Secondary Analysis of NRG Oncology-RTOG 0617 at 5-years
Tue, 12 Sep 2023 - 40min - 180 - MARS 2 in Spanish--Monday WCLC Highlights
MARS 2 in Spanish--Monday WCLC Highlights In this Spanish-language podcast, Lung Cancer Considered Host Dr. Narjust Florez enlists two colleagues to discuss the MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Guests: Dra. Rosanna Ruiz, Oncologo clínico Institutio nacional de enfermedades neoplásicas, Lima, Peru Dr. Ricardo Terra, Cirujano toracico Professor, the cirugia toracica en la universidad de Sao Paolo, Brazil
Tue, 12 Sep 2023 - 27min - 179 - Live from WCLC: Monday Highlights
Monday at WCLC 2023 features the Presidential Symposium. In this special WCLC 2023 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Eric Lim about MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Dr. Paula Ugalde, discussant for MARS 2, provides her unique overview and perspective on research presented today. The hosts also talk with Dr. P.C. Yang about the new results presented in the TALENT study of lung cancer screening in Taiwan. Emi Bossio, a patient research advocate and board member of Lung Cancer Canada adds her unique perspective. Additionally, Dr. Pasi Janne summarizes his presidential abstract: Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2) and is joined in a discussion with Emi Bossio, a patient with EGFR lung cancer. Professor Eric Lim is a Consultant Thoracic Surgeon at the Royal Brompton Hospital and Professor of Thoracic Surgery at the National Heart and Lung Institute of Imperial College London. Pan-Chyr Yang, MD, PhD--National Taiwan University College of Medicine and National Taiwan University Hospital, Institute of Biomedical Sciences, Genomics Research Center, Academia Sinica, Taiwan. Paula Ugalde – Dr. Paula Ugalde Figueroa, Thoacic Surgeon, Brigham and Women's Hospital Pasi Jänne is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute
Mon, 11 Sep 2023 - 54min - 178 - Live from WCLC: Sunday Highlights
Sunday highlights from WCLC 2023 include hosts Dr. Narjust Florez and Dr. Stephen Liu discussing two-year data from KRYSTAL-1 with Dr. Shirish Gadgeel; a discussion of the IASLC Language Guide and patient-centered language with noted lung cancer patient advocate Jill Feldman; and six-year follow-up data from CheckMate 227 with Dr. Solange Peters. Panelists: Shirish Gadgeel, MD is the Associate Director of Henry Ford Cancer Institute and the Chief of Division of Hematology/Oncology at Henry Ford Health. He is also Professor of Internal Medicine at Michigan State University. Jill Feldman, Lung Cancer Patient and Advocate, Twitter: Solange Peters, MD, PhD Chair and Professor, Medical Oncology, Full Professor, University Hospital of Lausanne, Lausanne, Switzerland.
Sun, 10 Sep 2023 - 35min - 177 - Title: Gender Equity and Beyond, a discussion with HRH Princess Dina Mired of Jordan
From lung cancer in women to gender equity in the healthcare workforce, IASLC is privileged to host HRH Princess Dina Mired of Jordan at the 2023 World Conference on Lung Cancer. In this special episode of Lung Cancer Considered, host Dr. Narjust Florez, IASLC President Dr. Heather Wakelee, and WCLC 2023 co-chair Dr. Fiona Hegi-Johnson discuss global advocacy through a gender equity lens, lessons learned from the field, and how HRH Dina Mired’s experience as the mother of a cancer survivor has impacted her work and initiatives globally.
Sat, 09 Sep 2023 - 1h 00min - 176 - IASLC Lung Cancer Considered Drug Development and Targeted Therapies
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses targeted therapies, what they are, and how they have changed our approach to treating not just lung cancer, but cancers in general. Guest: Dr. Vivek Subbiah Dr. Subbiah is the Chief of Early Phase Drug Development for Sarah Cannon Research Institute. He was previously the Executive Director of Medical Oncology Research for the MD Anderson Cancer Network, where he played a pivotal role in the development and ultimate approval for several agents that we consider essential in the lung cancer world.
Tue, 05 Sep 2023 - 50min - 175 - I want to be an oncologist: Where to start?
In this epidose of Lung Cancer Considered, Dr. Narjust Florez leads a discussion on the journey to an oncology fellowship. Medical training is long, full of sacrifices and student debt for many. For our listeners, after graduating from pre-med or undergraduate studies future physicians need to complete 4 years of medical school, followed by 3 years of internal medicine residency or 5 years of surgery or radiation oncology residency. For internal medicine residents they need to complete 3 to 4 additional years of hematology and oncology fellowship. Today we will be discussing recommendations for a smooth search, transition, and completion of an oncology fellowship. Guests: Dr. Christine Garcia, thoracic medical oncologist and fellowship program director at Weill Cornell Medicine in NYC. Dr. Regina Barragan-Carrillo, who completed her medical oncology fellowship in the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City and is currently a research fellow at City of Hope. Dr. Jennifer Marks, chief oncology fellow at Georgetown University with a focus on thoracic oncology.
Tue, 29 Aug 2023 - 43min - 174 - Lung Cancer Care in Mandarin: EGFR in China - From Testing to TreatingFri, 25 Aug 2023 - 56min
- 173 - Artificial Intelligence And Lung Cancer
Artificial intelligence is one of the most significant trends in most parts of society. Increasingly, oncologists and lung cancer researchers are including AI in research and patient care. In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of this compelling technology, focusing on its promise and limitations. Guests: Dr. Sanja Dacic, MD, PhD, MSc, an internationally renowned and highly accomplished leader in anatomic pathology and the Vice Chair and Director of Anatomic Pathology in the Department of Pathology at Yale School of Medicine. She currently serves as president of the Pulmonary Pathology Society. Dr. Fabio Ynoe de Moraes, MD, PhD, MBA - an Associate Professor and clinical investigator in radiation and global oncology at the Queen’s University and Kingston Health Sciences Centre, Kingston, ON, Canada. Dr Moraes has more than one hundred published peer-reviewed articles (i.e., NEJM, Lancet Oncology, Nature Medicine, Nature Biotechnology) and holds a PhD in Health Sciences (Oncology) and post graduate degree in artificial intelligence and machine learning and is one of the upcoming IASLC 2024 WCLC Chairs.
Tue, 15 Aug 2023 - 40min - 172 - LCC in Greek: Treating Lung Cancer in Greece
Greece ranks third in mortality in Europe from lung cancer, surpassed by Hungary and Serbia. In this episode of Lung Cancer Considered, host Dr. Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at the Henry Dunant Hospital in Athens, Greece, leads a discussion on the efforts from the Hellenic scientific community to implement smoking cessation strategies, screening programs, multidisciplinary approach and personalized treatment approaches of the Greek patient with lung cancer. Guests include: Helena Linardou is a Medical Oncologist, is Director of the 4th Oncology Dept and the Comprehensive Clinical Trials Center of Metropolitan Hospital in Athens, Greece. She completed a research Fellowship in Oncology and obtained her PhD Degree from Imperial College, University of London, UK Konstantinos Leventakos is a Medical Oncologist, assistant Professor at the Mayo Clinic in Rochester, USA, with a focus on thoracic malignancies, personalized medicine and immunotherapy.
Tue, 08 Aug 2023 - 1h 01min - 171 - IASLC Hot Topic in Basic and Translational Science Meeting Preview
This episode of Lung Cancer Considered previews the upcoming IASLC Hot Topic in Basic and Translational Science Meeting on Resistance to Immunotherapy in NSCLC. Joining host Dr. Stephen Liu are: Guests: Dr. Joachim Aerts, Professor of Pulmonary Oncology at Erasmus University Rotterdam and Head of Pulmonary Medicine at Erasmus MC in the Netherlands. Dr. Kellie Smith, Associate Professor of Oncology at Johns Hopkins University. Dr. Roberto Ferrara, Medical Oncologist and Immunologist, from Istituto Nazionale dei Tumori di Milano in Milan, Italy.
Fri, 04 Aug 2023 - 21min - 170 - Updated IASLC - Virtual Tumor Board On SCLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the management of small-cell lung cancer using a virtual tumor board format. SCLC is an aggressive subtype of lung cancer and for patients with advanced, or extensive-stage disease, the current first-line standard of care is chemo-immunotherapy. In the US and in Europe, the approved options are platinum and etoposide with a PDL1 inhibitor: either atezolizumab based on the IMpower 133 trial or durvalumab based on the CASPIAN trial.
Tue, 01 Aug 2023 - 49min - 169 - iMig Meeting Highlights
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discuss some of the highlights from iMig 2023 – the meeting of the International Mesothelioma Interest Group, an IASLC-endorsed meeting held in late June 2023 in Lille, France. Guests: Dr. Arnaud Scherpereel, the iMig President and 2023 Conference Chair, currently Professor of Pulmonary and Thoracic Oncology at the University Hospital of Lille. Dr. Jan van Meerbeeck, Professor of Thoracic Oncology at both Ghent and Antwerp University and Chair of Pulmonology at Antwerp University Hospital. He was also co-Chair of the 2023 iMig meeting
Tue, 18 Jul 2023 - 32min - 168 - IASLC - EGFR NSCLC In Brazil
This episode of Lung Cancer Considered examines the treatment of EGFR-positive lung cancer in Brazil from early-stage disease to metastatic lung cancer. Podcast guests: Dr. Juliana Ominelli, a Brazilian practicing medical oncologist in Rio de Janeiro, Brazil with experience treating EGFR Lung Cancer. She practices at the Brazilian National Cancer Institute –Oncologia DASA. Dr. Victor Marcondes, thoracic medical oncologist from Rio de Janeiro, Brazil who practices at Oncomed Oncologia and has led several trials in the region focusing on EGFR-positive NSCLC,
Tue, 04 Jul 2023 - 38min - 167 - Evolving Role of Liquid Biopsy for Lung Cancer
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion with two global experts about the current and future roles of liquid biopsy and its use for the treatment of lung cancer.
Tue, 20 Jun 2023 - 50min - 166 - IASLC - ASCO 2023 Highlights
In this episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu lead a discussion on the recently completed ASCO 2023 meeting that included presentation of the new overall survival data from the ADAURA trial as well as the New England Journal of Medicine publication on data from KEYNOTE 671.
Fri, 09 Jun 2023 - 57min - 165 - WCLC 2023 Preview: Singapore
WCLC 2023 is a global, multi-disciplinary meeting designed for physicians, nurses, clinicians, researchers, scientists, survivors and advocates. This year, the meeting rotates to Singapore and Lung Cancer Considered Hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by the meeting's three co-chairs for a wide-ranging interview about how attendees can make the most out of their experience during IASLC's flagship annual conference.
Tue, 06 Jun 2023 - 25min - 164 - LCC in Polish: Overcoming Barriers to Lung Cancer Therapy in Poland
LCC in Polish: Overcoming Barriers to Lung Cancer Therapy in Poland This special Polish-language episode of Lung Cancer Considered focuses on the unique challenges facing clinicians, researchers, and patients in Poland. The podcast also focuses on how physicians help patients overcome barriers to treating lung cancer. Host: Dr Anna Wrona, Department of Oncology and Radiotherapy, Medical University of Gdansk Guests: Professor Rafał Dziadziuszko, M.D., Ph.D., Head, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre at the Medical University of Gdańsk Professor Witold Rzyman, M.D., Ph.D. Head, Department of Thoracic Surgery at the Medical University of Gdańsk
Thu, 25 May 2023 - 27min - 163 - Lung Cancer Considered: Decoding ROS1 Fusions in Lung Cancer
In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses ROS+1 Fusions in NSCLC, including diagnosis, treatment and new exciting research coming down the pipeline. Her guests are: Dr. Lorenza Landi, Director of Clinical Trials Unit: Phase 1 and Precision Medicine at the National Cancer Institute Regina Elena in Rome. Dr. Landi has extensive experience and is interested in targeted therapy in lung cancer with a focus on ALK, HER-2/EGFR positive and ROS+1 lung cancer. Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology, at Henry Ford Cancer Institute in Detroit, Mich. Dr. Gadgeel is also part of the Lung Cancer steering committee for the Southwest Oncology Group and he is the Associate Editor of Clinical Lung Cancer and a reviewer for many journals.
Tue, 16 May 2023 - 40min - 162 - SCLC Transformation in EGFR NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on EGFR NSCLC and transformation to small cell lung cancer, a relatively new finding since the introduction of targeted therapy. Guests are: Dr. Shigeki Umemura Dr. Shigeki Umemura is from the Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan. His interests include targeted therapy in lung cancer, including genomic profiling of small cell lung cancer, evaluation of tumor microenvironment and its association with response to therapy and resistance mechanisms for disease progression. Dr. Zofia Piotrowska Dr. Zofia Piotrowska is an assistant professor of medicine at HMS and clinical researcher and lung cancer medical oncologist at the Massachusetts General Hospital. Dr. Piotrowska has an interest in understanding and overcoming resistance to targeted therapies in lung cancer, particularly among patients with EGFR-mutant NSCLC.
Tue, 02 May 2023 - 37min - 161 - Updated IASLC - ADAURA
Lung Cancer Considered hosts Dr. Narjust Flores and Dr. Stephen Liu talk with Dr. Roy Herbst about the ADAURA Trial. ADAURA introduced targeted therapy in the adjuvant setting for early-stage EGFR positive NSCLC. While we have seen targeted therapy in this space ADAURA showed DFS rates never seen before and changed the treatment of early-stage lung cancer.
Thu, 27 Apr 2023 - 40min - 160 - IASLC - Meeting the New JTO CRR Editor in Chief
In this episode of Lung Cancer Considered, host Dr. Narjust Florez interviews Dr. Emily Stone, the new editor of JTO Clinical and Research Reports. The podcast will focus on her article “Building on a Legacy”.
Tue, 18 Apr 2023 - 32min - 159 - IASLC - French Language Podcast
Host Dr. Alfredo Addeo, Senior Oncologist, Geneva University Hospital, in Geneva, Switzerland moderates a special French-language episode of Lung Cancer Considered focusing on managing locally advanced NSCLC. The guests for this special podcast are Dr. Cecile Le Pechoux, Radiation Oncologist at Department of Radiation Oncology Unit of Thoracic Oncology, Soft Tissue Sarcomas and Mesenchymal Tumour, and Dr. Jonathan Spicer, Associate Professor, Division of Thoracic Surgery. Director, McGill Thoracic Oncology Network, McGill University, Montreal General Hospital.
Tue, 11 Apr 2023 - 46min - 158 - IASLC - ELCC 2023 Highlights
This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Copenhagen. Host Dr. Stephen Liu, Dr. Heather Wakelee and Dr. Paul Van Schil discuss the important research presented at the meeting.
Thu, 06 Apr 2023 - 32min - 157 - IASLC - EGFR Mutant NSCLC Post Osimertinib
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a new Virtual Tumor Board on EGFR mutant NSCLC and acquired resistance. Dr. Liu is joined by two thoracic medical oncologists who are both global experts in targeted therapy.
Tue, 04 Apr 2023 - 31min - 156 - IASLC - LCC in Italian: Updates in Resectable NSCLCFri, 31 Mar 2023 - 52min
- 155 - IASLC - SCLC 2023 Meeting Preview
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a conversation about small cell lung cancer and previews the upcoming IASLC 2023 Hot Topic Meeting: Small Cell Lung Cancer in April which is focused on both preclinical and clinical advances in small cell lung cancer research. Joining the conversation are Alvaro Quintanal-Villalonga, PhD., from the Rudin Lab at Memorial Sloan Kettering Cancer Center in New York, and Kate Sutherland, PhD., from the Walter and Eliza Hall Institute of Medical Research in Australia.
Fri, 24 Mar 2023 - 24min - 154 - IASLC The Great Debate Dr. Einhorn Dr. Simone And Dr. Florez
In this episode of Lung Cancer Considered, recorded at the 2023 Targeted Therapies of Lung Cancer meeting, host Dr. Narjust Florez moderates a conversation about the use of consolidated radiation in early-stage small cell lung cancer. Joining the debate are Dr. Lawrence Einhorn from the Indiana University School of Medicine and Dr. Charles Simone from Memorial Sloan Kettering.
Tue, 21 Mar 2023 - 17min - 153 - LCC Targeted Therapy Recap
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a recap of the recent IASLC meeting, Targeted Therapies for Lung Cancer, or TTLC23 --a member-favorite, a relatively smaller meeting known for its fast pace and its breadth of content. Guests include, the two co-chairs of the meeting: Dr. Charu Aggarwal, thoracic medical oncologist at the Hospital of the University of Pennsylvania and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania. Dr. Joel Neal, thoracic medical oncologist and Associate Professor at Stanford University where he is also the Medical Director for the Cancer Clinical Trials Office.
Thu, 09 Mar 2023 - 38min - 152 - IASLC - Neoadjuvant
In this Virtual Tumor Board episode of Lung Cancer Considered, host Dr. Stephen Liu and his guests discuss the dynamic topic of managing resectable stage III NSCLC. Joining him are: Dr. Isabelle Schmitt-Opitz, Professor of Thoracic Surgery and Director of the Department of Thoracic Surgery at University Hospital of Zurich, Chair of the Lung Cancer Center of Zurich, and the President of the European Society of Thoracic Surgery. She received the IASLC Robert J Ginsberg Lectureship Award for Surgery at the 2022 World Conference on Lung Cancer. Dr. Jonathan Spicer, Medical Director of the Thoracic Oncology Program at McGill University in Montreal where he is the Advanced Thoracic and Upper GI Surgical Oncology Fellowship Program Director. He is also a co-author of the CheckMate 816 study. Dr. Tina Cascone, Assistant Professor and Thoracic Medical Oncologist at the University of Texas MD Anderson Cancer Center and Principal Investigator of the neoadjuvant NEOSTAR study.
Tue, 07 Mar 2023 - 45min - 151 - IASLC EGFR AM And PM
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on a specific subset of lung cancer: EGFR exon 20 insertion NSCLC. Joining the podcast are distinguished panel of clinicians and lung cancer advocates: Dr. Rosario Garcia Campelo, the Head of Medical Oncology and the Thoracic Tumor Unit Chair at the University Hospital A Coruna, Spain. Marcia Horn, executive director of the Exon 20 Group and CEO of ICAN, the International Cancer Advocacy Network. Yonsei University College of Medicine, Professor Byoung-Chul Cho, Director of the Lung Cancer Center at Yonsei Cancer Hospital in Seoul, South Korea.
Thu, 23 Feb 2023 - 39min - 150 - IASLC RET NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion about NSCLC with RET rearrangements, including diagnosis, treatment, and new exciting research coming down the pipeline. Podcast guests are: Dr. Justin Gainor, the Director of the Center for Thoracic Cancers at the Massachusetts General Hospital (MGH), Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies, and Co-Leader of the SU2C Lung Cancer Dream Team. His major research interests have focused on targeted therapy and immunotherapy. Dr. Lizza Hendricks, Assistant Professor at research institute GROW, School for Oncology and Developmental Biology of Maastricht University in the Netherlands. Her focus area is thoracic oncology, in particular prevention and optimal treatment of brain metastases in lung cancer and targeted therapy. Since 2019, Dr Hendriks has coordinated the clinical lung cancer research of the lung diseases department in Maastricht.
Wed, 22 Feb 2023 - 34min - 149 - IASLC - KRAS G12C
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a conversation on KRAS G12C mutation. Joining the podcast are Dr. Melissa Johnson, the Program Director of Lung Cancer Research at the Sarah Cannon Research Institute and Dr. Ferdinandos Skoulidis, an Associate Professor at the University of Texas MD Anderson Cancer Center.
Tue, 21 Feb 2023 - 33min - 148 - IASLC - LALCA Highlights
The Latin American Conference on Lung Cancer, held in Uruguay, wrapped up in late January. To provide a summary of key findings from the meeting, Lung Cancer Considered host Dr. Narjust Florez interviewed two prominent oncologists from South America: Dr. Clarissa Mathias, Dr. Mathias is a medical oncologist and director of NOB/Oncoclinicas in Brazil. She is a member of the ASCO International Quality Steering Group and Lung cancer committee. Dr. Mathias served on the IASLC board and has led many efforts in thoracic oncology in Brazil and recently hosted an episode of Lung Cancer Considered in Portuguese. Dr. Carlos Barrios, born in Uruguay but practicing oncologist in Brazil. Dr. Barrios is Director and Principal Investigator of the Oncology Research Center at Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul since 1996, where he has participated in more than 300 clinical research trials during the past 15 years. He is Director of Clinical Research and Oncologist of the Oncoclínicas Group in Porto Alegre. He is Adjunct Assistant Professor of the William Harrington Latin American Program of the University of Miami School of Medicine.
Tue, 07 Feb 2023 - 36min - 147 - IASLC FDA Approval Adjuvant Pembrolizumab For NSCLC
On January 26, 2023, the US FDA granted approval of pembrolizumab, an anti-PD-1 antibody, as an adjuvant therapy for patients with resected NSCLC. In this episode of Lung Cancer Considered host Dr. Stephen Liu leads a discussion on this approval with two thoracic medical oncologists with extensive expertise in this space: Dr. Jamie Chaft, an Associate Attending at Memorial Sloan Kettering Cancer Center, where she is the Director of Early Stage Lung Cancer Research, chair of the adjuvant nivolumab trial within the ALCHEMIST program and heavily involved in perioperative systemic therapy studies. Dr. Mary O’Brien, Professor and Consultant Medical Oncologist at the Royal Marsden in Surrey, Head of the Lung Unit, and chair of the EORTC Lung Cancer Group. She was one of the investigators on the KEYNOTE 091 trial which provided key data that lead to this approval.
Thu, 02 Feb 2023 - 30min - 146 - IASLC IPASS Study 2
In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator, Dr. Tony Mok. IPASS was a randomized phase III trial that compared the EGFR TKI gefitinib to carboplatin plus paclitaxel and showed, for the first time, that in a selected population, targeted therapy was superior to chemotherapy. The initial results were published in the New England Journal of Medicine in 2009 and helped usher in the era of precision oncology. Dr. Tony Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.
Wed, 25 Jan 2023 - 40min - 145 - Lung Cancer In Brazil with Clarissa Maria Cerqueira, Mathias Ticiana Leal And Carlos G. Ferreira
In a special episode of Lung Cancer Considered focusing on lung cancer in Brazil, host Dr. Clarissa Mathias, medical oncologist at Oncoclinicas Bahia and Hospital Santa Izabel, is joined by Dr. Ticiana Leal, associate professor, Department of Hematology & Oncology and director of Thoracic Medical Oncology, Winship Cancer Institute, Emory University and Dr. Carlos Gil Ferreira, president of Instituto Oncoclinicas and chief medical officer – Oncoclínicas.
Tue, 24 Jan 2023 - 29min - 144 - Patient Advocacy Groups with Janet Freeman-Daily, Seamus Cotter & Terri Conneran
Host Dr. Narjust Florez engages with three leading lung cancer patient advocates on the importance of patient advocacy groups, how these were formed, challenges when managing large patient advocacy groups and the future of patient advocacy in lung cancer. Janet Freeman-Daily is a cancer patient research advocate and activist who translates the experience and science of cancer for others. She was diagnosed with advanced lung cancer in 2011 and metastatic ROS1+ lung cancer in 2012. She collaborates, writes, and speaks with cancer organizations both internationally and within the USA, and blogs at Gray Connections. Seamus Cotter is from Ireland and was diagnosed with stage IV NSCLC lung cancer in June 2016 and has shared his experiences with immunotherapy on many global platforms. Since his diagnosis, Seamus has been involved in drug development and the improvement of clinical trials in lung cancer. He is deeply involved in the Irish Lung Cancer Community and is also a Patient Consultant on the lung group in Cancer Trials Ireland. Terri Conneran is one of the founders of the non-profit group “KRAS Kickers.” She was diagnosed with stage IIIa KRAS + lung cancer and has experienced separate recurrences and has persevered through multiple treatments and has dedicated her time to patient advocacy. Terri has shared her story on national and international platforms and created a community beyond lung cancer for all patients with KRAS-driven cancers.
Tue, 17 Jan 2023 - 49min - 143 - Radon with Hina Khan And Laura Mezquita
Radon exposure is a known risk factor for lung cancer yet it does not garner as much attention as other risk factors. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses radon, its impact on lung cancer diagnosis, new research covering radon and strategies to improve our patients and the general population's exposure to this radioactive gas. Her guest is Dr. Hina Khan, thoracic medical oncologist at the Lifespan Cancer Center and an assistant professor at The Warren Alpert Medical School of Brown University. Dr. Khan has studied the effect of radon in lung cancer and its genomic profile.
Tue, 03 Jan 2023 - 33min - 142 - Radiology - Management of Lung Cancer with Florian Fintelmann and Carole Ridge
Radiologists play central roles in the detection of lung cancer, in assessing response to therapy and relapse of disease and increasingly, interventional radiologists are involved with tissue sampling and lung cancer treatment. In this episode of Lung Cancer Considered, host Dr. Stephen Liu interviews two noted radiologists--Dr. Carole Ridge and Dr. Florian Fintelmann. Dr. Ridge is a consultant radiologist at Royal Brompton Hospital and a Senior Clinical Research Fellow at Imperial College London. Her research was awarded the Royal Academy of Medicine in Ireland medal in 2018. Dr. Florian Fintelmann is an Associate Professor at Harvard Medical School and a thoracic radiologist at Massachusetts General Hospital. He also leads the Thoracic Imaging Percutaneous Thermal Ablation program at the MGH.
Tue, 20 Dec 2022 - 36min - 141 - FDA Approval: Adagrasib with Sheena Bhalla and Joshua Sabari
This week, the FDA granted accelerated approval to Adagrasib to treat advanced NSCLC with a KRAS G12C mutation after at least one prior line of systemic therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu and two guests discuss the approval and what impact it will have on patients and clinicians. Joining the podcast are Dr. Joshua Sabari (@JSabari), assistant professor of Medicine and Thoracic Oncologist at NYU Perlmutter Cancer Center in New York City, and Dr. Sheena Bhalla (@SheenaBhallaMD), assistant professor of Medicine and Thoracic Oncologist at UT Southwestern Medical Center in Dallas.
Fri, 16 Dec 2022 - 30min - 140 - Lung Cancer in Israel with Alona Zer, Jair Bar and Nir Peled
In this special edition of Lung Cancer Considered, three oncologists and lung cancer experts explore lung cancer in Israel, spoken in Hebrew. Host Dr. Alona Zer, Head of the Department of Medical Oncology at the Rambam Health Care Campus, Haifa, Israel welcomes guests Dr. Jair Bar, Deputy Director, Institute of Oncology at Chaim Sheba Medical Center and Associate Professor of Oncology, School of Medicine at Tel Aviv University and Dr. Nir Peled, Head, the Cancer Institute at Shaare Zedek Medical Center and Full Professor, Internal Medicine & Medical Oncology, Faculty of Health Sciences at Ben-Gurion University of the Negev, Beer Sheva, Israel.
Fri, 16 Dec 2022 - 49min - 139 - ACLC & ESMO Asia 2022 Highlights
In this episode of Lung Cancer Considered, host Dr. Stephen Liu and invited guests to discuss the IASLC Asian Conference on Lung Cancer (ACLC) held in Japan and the ESMO Asia meeting held in Singapore. Guests include Dr. James Yang, director and Professor of the Graduate Institute of Oncology at the National Taiwan University and the director of the Department of Oncology at the National Taiwan University Hospital, Dr. Thanyanan Baisamut, consultant in the Division of Medical Oncology at Ramathibodi Hospital and Mahidol University in Thailand, and Dr. Takashi Setothor, thoracic medical oncologist from the National Kyushu Cancer Center in Fukuoka, Japan.
Tue, 13 Dec 2022 - 55min - 138 - Lung Cancer in the Middle East with Nagla Karim, Houssein Abdul Sater, and Abdelrahman Mohamed
In this special edition of Lung Cancer Considered, three oncologists and lung cancer experts explore lung cancer in the Middle East (North Africa), spoken in Arabic. Host Dr. Nagla Karim, MD, PHD, Director of the Phase I Program at the Inova Schar Cancer Institute welcomes guests Dr. Abdelrahman Mohamed, MD, Head of Thoracic Surgery, NCI at Cairo University and Dr. Houssein Abdul Sater, MD, Physician Scientist, Immuno-Oncology and Regional Research Director, Cancer Institute at Cleveland Clinic Florida.
Mon, 12 Dec 2022 - 31min - 137 - MET In NSCLC with Noemi Reguart and Ross Camidge
This episode of Lung Cancer Considered covers a subset of patients with non-small cell lung cancer with lung cancer -- MET exon 14 skipping mutations. MET exon 14 skipping mutations occur in approximately 3 to 4% of patients with NSCLC, typically in the absence of other driver mutations. Host Dr. Narjust Florez will discuss the unique clinical issues surrounding MET exon with Dr. Ross Camidge, Director of the Clinical and Research Thoracic Program at the University of Colorado and Dr. Noemi Reguart, Clinical Professor at the University of Barcelona.
Tue, 06 Dec 2022 - 46min - 136 - EMPOWER-Lung 3 with Jordi Remon and Isabel Preeshagul
This episode of Lung Cancer Considered is part of our series on FDA approvals of new lung cancer therapies. Today, host Dr. Stephen Liu discusses the EMPOWER-Lung 3 regimen of the PD-1 inhibitor cemiplimab with first-line platinum doublet chemotherapy for advanced NSCLC. This regimen was approved by the FDA on November 8, 2022. His guests are Dr. Jordi Remon, a thoracic medical oncologist who had previously practiced at Hospital de Mataro in Barcelona. He is now part of the esteemed thoracic unit at Gustave Roussy in Paris and the secretary of the Lung Cancer Group of EORTC. Joining Dr. Remon is Dr. Isabel Preeshagul, a thoracic medical oncologist and Assistant Attending with Memorial Sloan Kettering. She is also the chair of the Education and Engagement Committee of the Lung Cancer Research Foundation.
Tue, 29 Nov 2022 - 40min - 135 - The POSEIDON Trial With Tejas Patil
Dr. Narjust Florez discusses the POSEIDON trial with guest Dr. Tejas Patil, assistant professor at Thoracic Oncology Research Initiative, University of Colorado Cancer Center. This Phase III study led to the recent FDA approval of Tremelimumab in combination with Durvalumab and chemotherapy as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC).
Mon, 28 Nov 2022 - 33min - 134 - Evolution Of Stage III NSCLC with Martin Reck and Paula Antonia Ugalde Figueroa
In this episode of Lung Cancer Considered, host Dr. Stephen Liu, Director of Thoracic Oncology at Georgetown University, leads a discussion about the management of stage III NSCLC. Joining him are pulmonologist Dr. Martin Reck, Head of the Department of Thoracic Oncology and the Head of the Clinical Trials Department at the Lung Clinic Grosshansdorf and thoracic surgeon Dr. Paula Antonia Ugalde Figueroa, an Associate Surgeon in the Division of Thoracic Surgery at Brigham and Women’s Hospital in Boston, MA. Dr. Reck has led many of the oncology trials that have defined the standard of care for lung cancer including KEYNOTE-024 and more recent efforts in stage III NSCLC like KEYNOTE-799. Dr. Ugalde has been a pioneer in minimally invasive surgery from her time as director of Thoracic Oncology research at Laval University in Quebec to her current position at the Dana Farber Cancer Institute. She is currently a member of the Board of Directors of IASLC.
Tue, 15 Nov 2022 - 53min
Podcasts similar to Lung Cancer Considered
- Conversations ABC listen
- Global News Podcast BBC World Service
- El Partidazo de COPE COPE
- Herrera en COPE COPE
- The Dan Bongino Show Cumulus Podcast Network | Dan Bongino
- Es la Mañana de Federico esRadio
- La Noche de Dieter esRadio
- Hondelatte Raconte - Christophe Hondelatte Europe 1
- Affaires sensibles France Inter
- Dateline NBC NBC News
- Más de uno OndaCero
- La Zanzara Radio 24
- L'Heure Du Crime RTL
- El Larguero SER Podcast
- Nadie Sabe Nada SER Podcast
- SER Historia SER Podcast
- Todo Concostrina SER Podcast
- 安住紳一郎の日曜天国 TBS RADIO
- TED Talks Daily TED
- アンガールズのジャンピン[オールナイトニッポンPODCAST] ニッポン放送
- 辛坊治郎 ズーム そこまで言うか! ニッポン放送
- 飯田浩司のOK! Cozy up! Podcast ニッポン放送
- 吳淡如人生實用商學院 吳淡如
- 武田鉄矢・今朝の三枚おろし 文化放送PodcastQR